A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (300, 600, and 1200 mcg once daily) of GSK159802 in asthmatic patients.
Latest Information Update: 20 Aug 2023
At a glance
- Drugs GSK 159802 (Primary) ; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 21 Jun 2011 New trial record